Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 15, 2023

Asciminib Monotherapy for CML-CP Without BCR–ABL1 T315I Mutations Treated With ≥2 Prior TKIs

Leukemia

 

Additional Info

Disclosure statements are available on the authors' profiles:

Leukemia
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
Leukemia 2023 Mar 22;[EPub Ahead of Print], MJ Mauro, TP Hughes, DW Kim, D Rea, JE Cortes, A Hochhaus, K Sasaki, M Breccia, M Talpaz, O Ottmann, H Minami, YT Goh, DJ DeAngelo, MC Heinrich, V Gómez-García de Soria, P le Coutre, FX Mahon, JJWM Janssen, M Deininger, N Shanmuganathan, MB Geyer, S Cacciatore, F Polydoros, N Agrawal, M Hoch, F Lang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading